Abatacept SC — Competitive Intelligence Brief

Abatacept SC (Abatacept SC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Costimulation modulator; T cell inhibitor. Area: Immunology.

phase 3 Costimulation modulator; T cell inhibitor CD80, CD86 Immunology Small molecule

Target snapshot

Abatacept SC (Abatacept SC) — University Medical Center Groningen. Abatacept is a fusion protein that inhibits T cell activation by blocking the CD80/CD86 costimulatory signal required for full T cell engagement.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abatacept SC TARGET	Abatacept SC	University Medical Center Groningen	phase 3	Costimulation modulator; T cell inhibitor	CD80, CD86
Orencia	abatacept	Bristol-Myers Squibb	marketed	Selective T cell costimulation modulator	CD80, CD86, CD28	2005-01-01
Placebo matching with Abatacept	Placebo matching with Abatacept	Bristol-Myers Squibb	marketed	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Intravenous (IV) abatacept	Intravenous (IV) abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein; T-cell costimulation inhibitor	CD80, CD86
Double-blind Abatacept	Double-blind Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell co-stimulation inhibitor)	CD80, CD86
Subcutaneous (SC) abatacept	Subcutaneous (SC) abatacept	Bristol-Myers Squibb	phase 3	T-cell costimulation modulator	CD80/CD86
Abatacept plus	Abatacept plus	Massachusetts General Hospital	phase 3	T-cell costimulation modulator	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Costimulation modulator; T cell inhibitor class)

1. University Medical Center Groningen · 1 drug in this class